This inventor holds 4 USPTO granted patents and 3 EPO patents. Top assignee: Merck Sharp & Dohme LLC. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Michelle Machacek: Innovator in PRMT5 Inhibitors
Introduction
Michelle Machacek is a prominent inventor based in Belmont, MA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of PRMT5 inhibitors. With a total of 4 patents to her name, her work is paving the way for new treatments in various medical conditions.
Latest Patents
Among her latest patents, Michelle has developed compounds that serve as PRMT5 inhibitors. The first patent provides a compound of Formula (I) along with its pharmaceutically acceptable salts, esters, and prodrugs. These compounds are designed to treat cancer, sickle cell disease, and hereditary persistence of fetal hemoglobin (HPFH) mutations. The second patent also focuses on PRMT5 inhibitors, offering a selection of compounds A, B, C, and D, along with their respective pharmaceutical compositions and methods of use for similar medical conditions.
Career Highlights
Michelle Machacek is currently employed at Merck Sharp & Dohme LLC, where she continues to innovate in the pharmaceutical industry. Her work has been instrumental in advancing the understanding and treatment of complex diseases through her research and patent filings.
Collaborations
Throughout her career, Michelle has collaborated with notable colleagues such as Craig R. Gibeau and David L. Sloman. These partnerships have enhanced her research efforts and contributed to the successful development of her patented compounds.
Conclusion
Michelle Machacek stands out as a dedicated inventor in the field of pharmaceuticals, particularly with her innovative work on PRMT5 inhibitors. Her contributions are vital for the advancement of treatments for serious medical conditions, showcasing her commitment to improving patient outcomes.